Difference between revisions of "Part:BBa K4165006"

(→‎Dry Lab characterization)
(→‎Dry Lab characterization)
Line 20: Line 20:
  
 
<html>
 
<html>
−
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/td28rev.jpg" style="margin-left:200px;" alt="" width="250" /></p>
+
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/td28rev.jpg" style="margin-left:300px;" alt="" width="250" /></p>
 
</html>
 
</html>
  

Revision as of 18:36, 4 October 2022


TD28rev (Tau binding peptide)

A synthetic peptide that is used for targeting misfolded tau protein (BBa_K4165009) as it binds to PHF6 of tau fibrils.


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Usage and Biology

A short synthetic peptide acquired by mirror image phage display for binding to tau fibrils at its seed sequence ‘VQIVYK’ called the PHF6. The aggregation of microtubule-associated tau protein starts at this seed to form neurofibrillary tangles inside the brain, which are the main cause of Alzheimer’s disease (AD). Accordingly, this peptide would be suitable to act as our targeting domain for the aggregations.


Dry Lab characterization

Modeling

We modeled the peptide with (Alphafold2, Apptest, iTASSER, and trRrosetta) and our top model was obtained from Apptest scoring 6 out of 6 according to our quality assessment code.

References

Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow, E., ... & Funke, S. A. (2016). Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease. PLoS One, 11(12), e0167432.